Literature DB >> 16341050

Identification of circulating CD10 positive T cells in angioimmunoblastic T-cell lymphoma.

L Baseggio1, F Berger, D Morel, M-H Delfau-Larue, G Goedert, G Salles, J-P Magaud, P Felman.   

Abstract

In most cases of lymphomas with blood dissemination, the careful cytological analysis of peripheral blood smears provides a rapid orientation to diagnosis, even if the final subtyping is achieved by histology and eventually other techniques. Here, we evaluated if the analysis of blood smears may suggest the blood dissemination of angioimmunoblastic T-cell lymphoma (AITL) and if CD10 expression on neoplastic T cells, as recently reported on AITL, may contribute to the diagnosis. In all, 11 lymph nodes and six peripheral blood samples from 12 patients with AITL were studied using four-colour flow cytometry associated to histological, cytological and molecular data. According to previous results, a fraction of T cells expressed CD10 in 10/11 lymph nodes. Interestingly, all blood smears showed atypical lymphoid cells and a fraction of T cells expressed CD10 with a mean percentage of 18.75% (range 5.00-47.00%), regardless of lymphocytosis level and of rate of CD10 T cells in corresponding lymph node. In contrast, in all control samples (100), none CD10-positive T cell was identified. This is to our knowledge the first description of circulating CD10 neoplastic T cells in AITL. Therefore, they ought to be explored in further studies when aggressive lymphoma, in particular with lymphopenia and circulating atypical cells, is suspected.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16341050     DOI: 10.1038/sj.leu.2404013

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  12 in total

1.  Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells.

Authors:  Gabriel Brisou; Delphine Manzoni; Stephane Dalle; Pascale Felman; Dominique Morel; Marouane Boubaya; Jean Pierre Magaud; Lucile Baseggio
Journal:  J Clin Lab Anal       Date:  2014-03-20       Impact factor: 2.352

Review 2.  Follicular helper T cells: implications in neoplastic hematopathology.

Authors:  Philippe Gaulard; Laurence de Leval
Journal:  Semin Diagn Pathol       Date:  2011-08       Impact factor: 3.464

3.  Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.

Authors:  Sanam Loghavi; Sa A Wang; L Jeffrey Medeiros; Jeffrey L Jorgensen; Xin Li; Zijun Y Xu-Monette; Roberto N Miranda; Ken H Young
Journal:  Leuk Lymphoma       Date:  2016-04-22

4.  Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.

Authors:  Marie-Hélène Delfau-Larue; Laurence de Leval; Bertrand Joly; Anne Plonquet; Dominique Challine; Marie Parrens; Alain Delmer; Gilles Salles; Franck Morschhauser; Richard Delarue; Pauline Brice; Reda Bouabdallah; Olivier Casasnovas; Hervé Tilly; Philippe Gaulard; Corinne Haioun
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

5.  CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder.

Authors:  Guillaume Lefèvre; Marie-Christine Copin; Christophe Roumier; Hélène Aubert; Martine Avenel-Audran; Nathalie Grardel; Stéphanie Poulain; Delphine Staumont-Sallé; Julien Seneschal; Gilles Salles; Kamel Ghomari; Louis Terriou; Christian Leclech; Chafika Morati-Hafsaoui; Franck Morschhauser; Olivier Lambotte; Félix Ackerman; Jacques Trauet; Sandrine Geffroy; Florent Dumezy; Monique Capron; Catherine Roche-Lestienne; Alain Taieb; Pierre-Yves Hatron; Sylvain Dubucquoi; Eric Hachulla; Lionel Prin; Myriam Labalette; David Launay; Claude Preudhomme; Jean-Emmanuel Kahn
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

6.  A case of CD10-negative angioimmunoblastic T cell lymphoma with leukemic change and increased plasma cells mimicking plasma cell leukemia: A case report.

Authors:  Yasushi Adachi; Takuya Hino; Masahiko Ohsawa; Kazuhito Ueki; Tomoko Murao; Ming Li; Yunze Cui; Mitsuhiko Okigaki; Mitsuhiro Ito; Susumu Ikehara
Journal:  Oncol Lett       Date:  2015-07-14       Impact factor: 2.967

7.  The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation.

Authors:  Teresa Marafioti; Jennifer C Paterson; Erica Ballabio; Andreas Chott; Yasodha Natkunam; Manuel Rodriguez-Justo; Anne Plonquet; Socorro M Rodriguez-Pinilla; Wolfram Klapper; Martin-L Hansmann; Stefano A Pileri; Peter G Isaacson; Harald Stein; Miguel A Piris; David Y Mason; Philippe Gaulard
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

8.  The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.

Authors:  Guillaume Lefèvre; Marie-Christine Copin; Delphine Staumont-Sallé; Martine Avenel-Audran; Hélène Aubert; Alain Taieb; Gilles Salles; Hervé Maisonneuve; Kamel Ghomari; Félix Ackerman; Fanny Legrand; André Baruchel; David Launay; Louis Terriou; Christian Leclech; Chahera Khouatra; Chafika Morati-Hafsaoui; Myriam Labalette; Raphäel Borie; François Cotton; Noémie Le Gouellec; Franck Morschhauser; Jacques Trauet; Catherine Roche-Lestienne; Monique Capron; Pierre-Yves Hatron; Lionel Prin; Jean-Emmanuel Kahn
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

Review 9.  T-cell lymphomas, a challenging disease: types, treatments, and future.

Authors:  Helen Ma; Maher Abdul-Hay
Journal:  Int J Clin Oncol       Date:  2016-10-14       Impact factor: 3.402

10.  The Early Diagnostic Dilemma in Angioimmunoblastic T Cell Lymphoma with Excessive Plasma Cells Proliferation.

Authors:  Chunyan Wang; Xia Mao; Songya Liu; Cheng He; Ying Wang; Li Zhu; Yangyang Wang; Yicheng Zhang
Journal:  Case Rep Med       Date:  2021-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.